Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study

This post hoc analysis assessed the effects on cardiovascular risk factors of body weight, systolic blood pressure (SBP) and triglycerides after 28 weeks’ treatment with exenatide once weekly plus dapagliflozin, as compared with exenatide once weekly or dapagliflozin, in patient subpopulations from...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Jabbour, Serge A., Frías, Juan P., Guja, Cristian, Hardy, Elise, Ahmed, Azazuddin, Öhman, Peter
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2018
Témata:
Brief Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969082/
https://ncbi.nlm.nih.gov/pubmed/29316164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13206
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky